4.7 Review

Postbiotics and Kidney Disease

期刊

TOXINS
卷 14, 期 9, 页码 -

出版社

MDPI
DOI: 10.3390/toxins14090623

关键词

chronic kidney disease; postbiotics; prebiotics; probiotics; hyperoxaluria; Oxalobacter formigenes; GABA-salt

资金

  1. European Union's Horizon 2020 Research and Innovation Program [860329]
  2. FIS/Fondos FEDER [PI18/01366, PI19/00815, PI21/00251]
  3. ERA-PerMedJTC2018 [KIDNEY ATTACK AC18/00064]
  4. Comunidad deMadrid en Biomedicina [B2017/BMD-3686 CIFRA2-CM]
  5. Instituto de Salud Carlos III (ISCIII) RICORS program [RI-CORS2040 (RD21/0005/0001)]
  6. European Union-NextGe-nerationEU, Mecanismo para la Recuperacion y la Resiliencia (MRR) [SPACKDc PMP21/00109]
  7. MICINN Ramon y Cajal program [RYC2018-024461-I]

向作者/读者索取更多资源

Chronic kidney disease (CKD) is expected to become the fifth leading cause of death globally by 2040 due to limitations in current diagnostic and treatment methods. The holobiont concept, which considers the host and its microbial community, may improve our understanding of kidney disease. Postbiotics, which refer to preparations of inanimate microorganisms and/or their components that benefit the host, have potential clinical applications in kidney disease. This article reviews the revised concept of postbiotics and discusses various formulations being developed for kidney disease, providing a roadmap for future research.
Chronic kidney disease (CKD) is projected to become the fifth global cause of death by 2040 as a result of key shortcomings in the current methods available to diagnose and treat kidney diseases. In this regard, the novel holobiont concept, used to describe an individual host and its microbial community, may pave the way towards a better understanding of kidney disease pathogenesis and progression. Microbiota-modulating or -derived interventions include probiotics, prebiotics, synbiotics and postbiotics. As of 2019, the concept of postbiotics was updated by the International Scientific Association of Probiotics and Prebiotics (ISAPP) to refer to preparations of inanimate microorganisms and/or their components that confer a health benefit to the host. By explicitly excluding purified metabolites without a cellular biomass, any literature making use of such term is potentially rendered obsolete. We now review the revised concept of postbiotics concerning their potential clinical applications and research in kidney disease, by discussing in detail several formulations that are undergoing preclinical development such as GABA-salt for diet-induced hypertension and kidney injury, sonicated Lactobacillus paracasei in high fat diet-induced kidney injury, GABA-salt, lacto-GABA-salt and postbiotic-GABA-salt in acute kidney injury, and O. formigenes lysates for hyperoxaluria. Furthermore, we provide a roadmap for postbiotics research in kidney disease to expedite clinical translation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据